Relmada Therapeutics (RLMD)
(Delayed Data from NSDQ)
$2.77 USD
-0.03 (-1.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.74 -0.03 (-1.08%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth C Momentum C VGM
Relmada Therapeutics, Inc. (RLMD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.17 | $10.00 | $2.00 | 84.64% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Relmada Therapeutics, Inc. comes to $5.17. The forecasts range from a low of $2.00 to a high of $10.00. The average price target represents an increase of 84.64% from the last closing price of $2.80.
Analyst Price Targets (3 )
Broker Rating
Relmada Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 2.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 2.60 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, two are Strong Buy, representing 40% of all recommendations. A month ago, Strong Buy represented 40%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/RLMD.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 0 |
ABR | 2.60 | 2.60 | 2.60 | 3.00 | 2.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
6/5/2024 | Goldman Sachs | Andrea Tan | Hold | Strong Sell |
3/20/2024 | Guggenheim Securities | Yatin Suneja | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.60 |
ABR (Last week) | 2.60 |
# of Recs in ABR | 5 |
Average Target Price | $5.17 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 253 |
Current Quarter EPS Est: | -0.56 |